Gastric cancer (GC) is one of the most malignant epithelial tumors. The incidence of GC varies worldwide, and nearly half of the cases occur in Asian countries, especially in Japan and China. GC is the second leading cause of cancer-related deaths in the world, and current prognosis of advanced GC remains dismal despite improvements in diagnosis and therapy. Our current study aimed to identify significant long noncoding RNAs (lncRNAs) that could be used for prognosis and for the elucidation of associated molecular mechanisms. This study identified a substantial variety of reports using high-throughput lncRNA detection to investigate the expression of lncRNAs in GC development. However, the reported potentially diagnostic lncRNAs were unsuitable for meta-analysis, so we verified the expression of diagnostic lncRNAs and selected eight of them using Gene Expression Profiling Interactive Analysis (GEPIA). Next, we explored interactions of selected lncRNAs using Qiagen’s IPA system. We also identified differentially expressed genes (DEGs) of GC using the GEO2R online tool and datasets GSE52149, GSE19826, and GSE79973. To reveal genes that could be regulated by the selected lncRNA in GC, we used a Venn diagram and selected IGF2BP3 and FOLR1 as potential downstream targets of lncRNAs H19 and PVT1, respectively. Expression of IGF2BP3 and FOLR1 in GC validated by GEPIA was related to the worse prognosis for GC patients as shown by Kaplan Meier plots. Considering that IGF2BP3 promotes the expression of H19 and PEG10, down-regulation of their expression may improve the prognosis for GC patients, although at this time there is no evidence for direct involvement of IGF2BP3 in the regulation of these lncRNAs. The second DEG, FOLR1, is a crucial component of cell metabolism and DNA synthesis/repair required for cancer cell division. However, the role of FOLR1 in the etiology and progression of GC requires further study. In conclusion, using an integrated bioinformatic approach we identified eight significantly altered lncRNAs with diagnostic potential in GC patients. We also identified two axes - H19-IGF2BP3 and PVT1-FOLR1 – that may be related to the prognosis of GC and provide new insights into the etiology of GC and management of GC patients.